HC Wainwright & Co. Initiates Coverage On Enveric Biosciences with Buy Rating, Announces Price Target of $10
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Vernon Bernardino has initiated coverage on Enveric Biosciences (NASDAQ:ENVB) with a Buy rating and set a price target of $10.
January 30, 2024 | 11:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Enveric Biosciences receives a Buy rating from HC Wainwright & Co. with a price target of $10, indicating a positive outlook from the analyst.
The initiation of coverage by an analyst with a Buy rating typically suggests a positive outlook on the stock's future performance. The price target of $10 implies a significant upside potential from the current trading price, which could attract investor interest and potentially drive up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100